Compare IPSC & BAFN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IPSC | BAFN |
|---|---|---|
| Founded | 2019 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Savings Institutions |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.8M | 40.6M |
| IPO Year | 2021 | N/A |
| Metric | IPSC | BAFN |
|---|---|---|
| Price | $0.58 | $7.97 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 934.8K | 6.7K |
| Earning Date | 11-13-2025 | 01-29-2026 |
| Dividend Yield | N/A | ★ 1.98% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $113,337,000.00 | $58,931,000.00 |
| Revenue This Year | $1,590.09 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4122.69 | N/A |
| 52 Week Low | $0.34 | $6.40 |
| 52 Week High | $1.38 | $19.75 |
| Indicator | IPSC | BAFN |
|---|---|---|
| Relative Strength Index (RSI) | 56.92 | 39.94 |
| Support Level | $0.50 | $7.90 |
| Resistance Level | $0.62 | $8.49 |
| Average True Range (ATR) | 0.04 | 0.13 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 64.59 | 12.39 |
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.